Comparable stake leader
James B. Breitmeyer
SEC ownership of Oncternal Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001260990.
Disclosed value leader
James B. Breitmeyer
Comparable rows
0/17
Latest evidence
30 Jun 2026
- Parsed ownership sources
-
3/4/5 and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
James B. Breitmeyer
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001260990
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Oncternal Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
James B. Breitmeyer
Disclosed value leader
James B. Breitmeyer
Comparable rows
0/17
Latest evidence
30 Jun 2026
3/4/5
13F
Highest disclosed value: $325,311
17 rows are not safely comparable across share classes.
Showing 1-8 of 17 holder rows.
Quick read
James B. Breitmeyer has the largest disclosed position value at $325.3K.
0 of 17 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens James B. Breitmeyer's linked filing trail.
Disclosed position value
Top 5
James B. Breitmeyer
$325.3K
HALE DAVID F
$283K
Robert James Wills
$89.6K
Richard G. Vincent
$73.1K
Salim Yazji
$63.8K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 17 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| James B. Breitmeyer |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$325,311
690,337 shares
mixed-class rows
|
— | 14 Feb 2024 |
| HALE DAVID F |
3/4/5
Director
|
—
mixed-class rows
|
$282,989
34,604 shares
mixed-class rows
|
— | 20 Jun 2024 |
| Robert James Wills |
3/4/5
Director
|
—
mixed-class rows
|
$89,613
12,200 shares
mixed-class rows
|
— | 20 Jun 2024 |
| Richard G. Vincent |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$73,066
161,482 shares
mixed-class rows
|
— | 14 Feb 2024 |
| Salim Yazji |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$63,816
142,835 shares
mixed-class rows
|
— | 14 Feb 2024 |
| Gunnar F. Kaufmann |
3/4/5
Chief Scientific Officer
|
—
class O/S missing
|
$46,994
94,726 shares
|
— | 12 Jun 2023 |
| Chase C. Leavitt |
3/4/5
General Counsel/Secretary
|
—
mixed-class rows
|
$42,048
98,958 shares
mixed-class rows
|
— | 14 Feb 2024 |
| Rajesh Krishnan |
3/4/5
CTO/CSO
|
—
mixed-class rows
|
$21,838
61,719 shares
mixed-class rows
|
— | 14 Feb 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Oncternal Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
James B. Breitmeyer
Net 12M change
$0
Latest report
20 Jun 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| James B. Breitmeyer | Chief Executive Officer, Director | $325,311 | Mixed | 14 Feb 2024 | ||
| HALE DAVID F | Director | $282,989 | Mixed | 20 Jun 2024 | ||
| Robert James Wills | Director | $89,613 | Filing P/S | 20 Jun 2024 | ||
| Richard G. Vincent | Chief Financial Officer | $73,066 | Mixed | 14 Feb 2024 | ||
| Salim Yazji | Chief Medical Officer | $63,816 | Mixed | 14 Feb 2024 | ||
| Gunnar F. Kaufmann | Chief Scientific Officer | $46,994 | Mixed | 12 Jun 2023 | ||
| Chase C. Leavitt | General Counsel/Secretary | $42,048 | Mixed | 14 Feb 2024 | ||
| Rajesh Krishnan | Cto/Cso | $21,838 | Mixed | 14 Feb 2024 | ||
| William R. Larue | Director | Mixed | 20 Jun 2024 | |||
| Rosemary Mazanet | Director | Mixed | 20 Jun 2024 | |||
| Daniel L. Kisner | Director | Mixed | 20 Jun 2024 | |||
| Michael G. Carter | Director | Mixed | 20 Jun 2024 | |||
| Jill DeSimone | Director | Mixed | 20 Jun 2024 | |||
| Charles Theuer | Director | Mixed | 20 Jun 2024 | |||
| Jinzhu Chen PhD | Director | Mixed | 16 Jun 2022 | |||
| Xin Nakanishi | Director | Mixed | 28 Jun 2023 |
Recent insider transactions for Oncternal Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.